Boston Scientific (NYSE:BSX) Reaches New 12-Month Low – Here’s What Happened

Boston Scientific Corporation (NYSE:BSX)’s stock price reached a new 52-week low during trading on Wednesday . The stock traded as low as $51.46 and last traded at $50.8310, with a volume of 6969715 shares traded. The stock had previously closed at $57.64.

Wall Street Analyst Weigh In

BSX has been the topic of several recent research reports. Evercore dropped their price target on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Oppenheimer set a $90.00 price objective on Boston Scientific in a report on Thursday, April 23rd. Weiss Ratings downgraded Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Robert W. Baird dropped their target price on Boston Scientific from $78.00 to $75.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Finally, Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Boston Scientific Price Performance

The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The stock has a market cap of $77.31 billion, a PE ratio of 21.77, a PEG ratio of 1.06 and a beta of 0.62. The business has a 50-day moving average price of $61.52 and a 200 day moving average price of $79.54.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, research analysts forecast that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other news, Director David C. Habiger bought 2,250 shares of the stock in a transaction on Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have bought 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors have recently added to or reduced their stakes in BSX. Vanguard Group Inc. boosted its position in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares during the last quarter. State Street Corp raised its stake in Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors lifted its position in Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank bought a new stake in Boston Scientific during the fourth quarter valued at approximately $2,199,395,000. Finally, Morgan Stanley grew its stake in Boston Scientific by 10.8% in the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after buying an additional 2,246,308 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.